ELTX Stock Forecast & Price Target

Elicio Therapeutics is viewed positively because its AMP platform has generated unusually strong and reproducible immune responses, with 99% of the first 90 evaluable Phase 2 AMPLIFY patients showing mKRAS-specific T cell activity and 87% of tested patients demonstrating antigen spreading, while Phase 1 data tied stronger T cell responses to an 88% lower relapse risk and median OS of 28.94 months. The company’s lead asset, ELI-002 7P, is differentiated as an off-the-shelf, lymph node-targeted vaccine against seven common KRAS mutations, supported by a clean safety profile with no dose-limiting toxicities, no cytokine release syndrome, and only mild Grade 1 fatigue and malaise as common events. Strategically, the program addresses a large unmet need in adjuvant PDAC and CRC, while also benefiting from reduced manufacturing complexity, multi-target coverage that may limit immune escape, and a platform that can extend to ELI-007 and ELI-008 without re-engineering.

Elicio Therapeutics is viewed negatively because its value depends heavily on ELI-002 7P, a single clinical asset that still faces major uncertainty in Phase 2 and may require additional trials even if it meets its DFS endpoint. The company’s own framework assumes a 65% probability of approval, yet the investment case is offset by risks of weak efficacy data, failure to reach pivotal development, regulatory rejection, and slower-than-expected adoption. Financially, the cash runway extends through 4Q26, but the need for additional capital before profitability creates meaningful dilution risk, while the small, uncontrolled Phase 1 dataset and heavy dependence on MIT-controlled patents weaken confidence in commercialization.